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suppression (OFS) added to T or to an aromatase inhibitor 
(AI) has radically changed the endocrine treatment land-
scape in this setting. In the joint analysis of TEXT and 
SOFT, OFS plus exemestane (E) was superior in terms of 
DFS to OFS plus T without difference in OS. In premeno-
pausal women receiving an AI complete OFS must be 
obtained usually using a gonadotropin-releasing hormone 
agonist GnRHa. However, incomplete OFS is expected in 
approximately 20% of the patients receiving a GnRHa plus 
AI. Hence when a GnRHa plus an AI is chosen, a continu-
ous monitoring of treatment adherence and the possible 
signs that suggest potential recovery of ovarian function-
are critical. Estradiol and FSH monitoring during treat-
ment can be considered.
Patients and methods: From 6/2017 to 12/2019 twenty-one 
consecutive premenopausal women with hormone positive 
HER2 negative early breast cancer participated in the observa-
tional study. The treatment was leuprolide (L) 3.75 mg every 4 
weeks plus E 25 mg daily. 14 pts received treatment after 
chemotherapy (CT) and 7 as monotherapy (M). The serum 
levels of E2, FSH and LH were assayed prior the administra-
tion of L plus E and then 1, 3, 6, 9 and 12 months after starting 
therapy. The laboratory standard values for menopausal levels 
are 10-40 pg/mL for E2 (limit detection 5 pg/ml), 25.8–134.8 
mIU/ml for FSH and 7.7-58.5 mIU/ml for LH.
Results: All pts completed the observational period. The 
baseline E2 value was menopausal in 8/14 CT pts and nor-
mal in all M pts. After 1 month E2 value was menopausal 
in 12/14 CT pts and normal in all M pts. Three-months E2 
values showed menopausal status in 13/14 CT pts and in 
5/7 M pts. At six months from the start, the hormonal sta-
tus remained unchanged therefore after discussion with 
these pts switched toT. At 12 months all pts in L plus E 
were in menopausal status. FSH and LH levels showed a 
marked reduction from the start of treatment.
Conclusions: The majority of the pts (18/21), regardless 
CT or M, had menopausal E2 value within six months 
from the start, special attention should be given to chemo-
therapy-naïve pts.
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Background: The immune system has a role in breast 
tumor, in particular in triple negative (TNBC) and in hor-
mone receptor-negative/HER2-positive breast cancers. 
The aim of this study is to analyze the association between 
baseline cytokines expression with cancer relapse and 
outcome.
Material and methods: Baseline plasmatic samples of 66 
stage I-III breast cancers treated with surgery with or with-
out radiotherapy and systemic treatment between 2011 and 
2017 were collected. A panel of 24 cytokines were ana-
lyzed by Luminex MAGPIX technology, using multiplex 
Luminex Magnetic Assay kits (®R&D System).
Results: Sixty-six breast cancer patients were included in the 
study. The median follow-up was of 78 months (range 
18-99). The median age at diagnosis was of 58.5 years (range 
32-86). The stage at diagnosis was I in 29 (43.9%) patients, 
II in 26 (39.4%) and III in 11 (16.7%). The histological type 
was ductal in 47 cases (71.2%), lobular in 13 (19.7%) and 
mixed in 6 (9.1%). Fifty-three (80.3%) patients were estro-
gen-receptor-positive, 11 (16.7%) HER2-positive and 12 
(18.2%) TNBC. All the patients received surgery, combined 
with neo/adjuvant chemotherapy in 35 (53%) cases, anti-
HER2 in 9 (13.6%), hormonotherapy in 53 (80.3%) and 
radiotherapy in 52 (78.8%). During the follow-up we 
observed 11 relapses and 4 deaths. IL-4 was associated with 
relapse, that occurs in 30.7% of the cases in the group with 
IL-4 > 0.07 (IL4-H) mean fluorescence intensity (MFI) vs in 
7.5% in the group with IL-4 ⩽ 0.07 MFI (IL4-L) (p 0.013), 
with a ROC curve AUC of 0.745. In multivariate analysis 
relapse was associated with IL-13 (p 0.048) and T stage (p 
0.049). Survival analysis showed a better time to treatment 
failure (TTF) for the group IL4-L (5y-TTF 87% vs 63% for 
IL4-L and IL4-H, p 0.022) and for the group with IL-13 ⩽ 
0.1 MFI (IL13-L) compared IL-13 > 0.1 MFI (IL13-H) (5y-
TTF 90% vs 45%, p 0.017). A separation of the curves was 
also observed for breast cancer specific survival (5y-BCSS: 
95% vs 84% for IL4-L vs IL4-H, p 0.118; 91% vs 75% for 
IL13-L vs IL13-H, p 0.029).
Conclusions: Higher baseline plasmatic level of IL-4 and 
IL-13 are associated with a worse prognosis in early stage 
breast cancer. These are two structurally and functionally 
related cytokines known for regulating the immune system 
activity, leading to a T helper-2 response and to a mac-
rophage M2 polarization. Data should be confirmed in a 
larger cohort and a mechanistic study is advisable.
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Background: Breast Cancer (BC) is the most common 
oncological disease diagnosed in pre-menopausal women. 
